Estimates of HCV-1 patients attaining rvr following dual therapy with peg-interferon and ribavirin

Digestive Diseases and Sciences

Volumn 58, Issue 5, 2013, Pages 1371-1382

  Andriulli, A ^a   Iacobellis, A ^a   Valvano, M R ^a   Spirito, F ^a   Ippolito, A ^a   Bossa, F ^a   Terracciano, F ^a   Fontana, R ^a   Niro, G ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Chronic viral hepatitis; Ethnicity; HCV; HCV infection; Peg interferon; Race; Ribavirin; Therapy

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; ASIAN; CAUCASIAN; ETHNICITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; VIREMIA; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84878681771     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2484-x     Document Type: Article

References (63)

1. Hezode Ch, Forrestier N, Dusheiko G, et al. Telaprevir and Peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2011;360:1839-1850.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-2416.
3. Poordard F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
4. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492.
5. Reichard O, Norkrans G, Fryden A, et al. Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet. 1998;351:83-87.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-965.
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
8. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced vial clearance. Nature. 2009;461:1100-1104.
9. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kd)/ribavirin. J Hepatol. 2005;43:425-433.
10. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin. Hepatology. 2006;43:950-954.
11. Mangia A, Thompson AJ, Santoro R, et al. Limited utility of IL28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 2011;54:772-780.
12. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized controlled trials and implications for the future. Hepatology. 2011;54:789-800.
13. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2b (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708.
14. Borenstein M, Hedges VH, Higgins JPT, et al. Identifying and Quantifying Heterogeneity in Introduction to Meta-analysis. Chichester UK: Wiley; 2009:107-113.
15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
16. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
17. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589-624.
18. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
19. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
20. Benhamou Y, Afdhal NH, Nelson DR, et al. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSer1 results. Hepatology. 2009;50:717-726.
21. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086-1097.
22. Bonardi R, Tabone M, Manca A, et al. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomed Pharmacother. 2011;65:303-306.
23. Brandao C, Barone A, Carrilho F, et al. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat. 2006;13:552-559.
24. Buti M, Zakharova NG, Blokhina NP, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010;52:1201-1207.
25. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470-477.
26. Di Bisceglie A, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hep. 2007;14:721-729.
27. Escudero A, Rodriguez F, Serra MA. del et al. Pegylated α-interferon-2a plus ribavirin compared with pegylated α-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008;23:861-866.
28. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2b and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451-458.
29. Fried M, Jensen DM, Rodriguez-Torres M, et al. Improved outcome in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon α-2b and ribavirin. Hepatology. 2008;48:1033-1043.
30. Grasso A, Malfatti F, De Leo P, et al. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol. 2009;51:984-990.
31. Hadziyannis SJ, Sette HJ, Morgan TR, et al. Peginterferon- alpha2a (40KD) and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
32. Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis. 2010;201:751-759.
33. Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon α-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol. 2009;104:70-75.
34. Ikeda H, Suzuki M, Okuse C, et al. Short-term prolongation of pegylated interferon and ribavirin for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res. 2009;39:733-759.
35. Kwo PY, McCone J, Schiff ER, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection "(SPRINT-1): an open-label, randomised, multicenter phase 2-trial. Lancet. 2010;376:705-716.
36. Liu CH, Liu CJ, Liang CC, et al. Pegylated interferon α-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260-1269.
37. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47:43-50.
38. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-593.
39. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New Engl J Med. 2009;360:1827-1838.
40. Mimidis K, Papadopoulos VP, Elefsiniotis I, et al. Hepatitis C survival curve analysis in naïve patients treated with peginterferon α-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastroint Liver Dis. 2006;3:213-219.
41. Napoli N, Giannelli G, Antonaci A, et al. The use of different peg-interferon α-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. J Viral Hep. 2008;15:300-304.
42. Nomura H, Miyahi Y, Tanimoto H, et al. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices. J Gastroenterol. 2009;44:338-345.
43. Poordard F, Lawitz E, Shiffman ML, et al. Virologic response rates of weight-based taribavirin versus ribavirin in treatment naïve patients with genotype 1 chronic hepatitis C. Hepatology. 2010;52:1208-1215.
44. Reddy KR, Shiffman ML, Rodriguez-Torres M, et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterology. 2010;139:1972-1983.
45. Roberts SK, Weltman MD, Crawford DHG, et al. Impact of high-dose peginterferon alfa-2a on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology. 2009;50:1045-1055.
46. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257-267.
47. Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-α2a plus ribavirin vs peginterferon-α2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138:108-115.
48. Sánchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 vs 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451-460.
49. Sebastiani G, Ferrari A, Boccato S, et al. Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV-1 positive patients with chronic hepatitis C. Aliment Pharmacol Ther. 2007;26:1077-1082.
50. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884-1893.
51. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with Peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia. J Hepatol. 2006;44:97-103.
52. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010;139:1257-1266.
53. Rodriguez-Torres M, Sulkowski MS, Chung RT, et al. Factors associated with rapid and early virologic response to peginterferon alfa-2b/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hep. 2010;17:139-147.
54. Reddy KR, Messinger D, Popescu M, et al. Peginterferon alfa-2a (40 kDa) and ribavirin: comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients. J Viral Hep. 2009;16:724-731.
55. Muir AJ, Hu KQ, Gordon SC, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hep. 2011;18:e134-e143.
56. Cheng WSC, Roberts SK, McGaughan G, et al. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic response. J Hepatol. 2010;53:616-623.
57. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014-1024.
58. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433-1444.
59. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344-350.
60. McHutchison JG. The role of genetic markers in hepatitis C therapy: a major step for individualized care. Liver Int. 2011;31:29-35.
61. Boceprevir EU Summary of Product Characteristics [online]. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-information/ Human/002332/WC500109786.pdf. Accessed on 19 November 2011.
62. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest predictor of sustained virologic response in genotype 1 Hepatitis C Virus. Gastroenterology. 2010;139:120-129.
63. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012;156:279-290.